SEESTEM OPERATORS

Industry Report

The Iberian Fertility Clinics Sector

January 2026

Report Index

Disclaimer

This document and any accompanying materials (together, the "Materials") contain certain forward-looking statements, projections, forecasts, and estimates (collectively, "Forward-Looking Statements") that reflect the current views and assumptions of the preparer with respect to future events and financial performance. These Forward-Looking Statements involve inherent risks, uncertainties, and contingencies, many of which are beyond the control of the preparer or any presenting entity. Actual results may differ materially from those expressed or implied herein. No assurance can be given that future developments will be in accordance with any expectations, and the preparer undertakes no obligation to update or revise any statements made herein, whether as a result of new information, future events, or otherwise.

The information contained in these Materials is provided for informational purposes only and does not constitute any representation, warranty, or guarantee, whether express or implied, as to the accuracy, completeness, or reliability of such information. Neither the preparer, nor any of its affiliates, officers, directors, employees, agents, or representatives accept any liability whatsoever for any direct, indirect, or consequential loss or damage arising from the use of or reliance on these Materials, or any information contained herein. The recipient acknowledges that it is solely responsible for conducting its own independent evaluation and analysis of the information.

These Materials are confidential and may contain proprietary or commercially sensitive information. They are being provided on a strictly private and confidential basis and may not be reproduced, distributed, disclosed, or used for any other purpose, in whole or in part, without the prior written consent of the preparer. By accepting these Materials, the recipient agrees to maintain their confidentiality and not to disclose any information contained herein to any third party without such prior consent.

These Materials are intended solely for distribution to professional, institutional, or qualified investors, and in jurisdictions where such distribution is legally permissible. They are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable laws or regulations, or which would subject the preparer or any affiliated entity to registration, licensing, or other regulatory requirements. Any recipient of these Materials is solely responsible for ensuring compliance with all applicable laws and regulations in their respective jurisdiction.

Nothing contained in these Materials constitutes, or should be construed as, an offer to sell or a solicitation of an offer to buy any securities or financial instruments, or to enter into any transaction. These Materials do not constitute investment advice, legal advice, or a recommendation with respect to any investment strategy or financial product. Any offer or solicitation, if made, will be made solely by means of a formal offering memorandum or other definitive documentation prepared and distributed in accordance with applicable laws and regulations.

Executive Summary

The Iberian Fertility Clinics Sector encompasses clinical providers, laboratories, and associated services delivering assisted reproductive technologies across Spain and Portugal. Spain operates as Europe's largest and most internationally oriented assisted reproduction market, distinguished by liberal donor regulations, comprehensive treatment offerings, and a robust cross-border patient ecosystem. Portugal maintains a regulated public framework complemented by expanding private capacity and ongoing regulatory refinements. Together, these markets form a bifurcated yet interconnected landscape shaped by divergent regulatory regimes, payer dynamics, and clinical service complexity.

Spain's market is characterized by high treatment volumes—accounting for approximately 12 percent of births via ART in 2022 and over 165,000 IVF cycles annually—supported by a dense network of more than 400 fertility centers and a mature donor program infrastructure. The country's permissive donor anonymity rules and broad treatment menu attract substantial cross-border demand, with international patients comprising more than half of the patient base at leading clinics. This cross-border activity expands the total addressable market well beyond the resident population and positions Spain as a European hub for donor egg programs, preimplantation genetic testing, and fertility preservation services.

Portugal presents a contrasting profile: a regulated public healthcare framework with documented access constraints, including significant waiting times and regional capacity gaps, alongside a growing private sector operating within the national Procriação Medicamente Assistida framework. Regulatory oversight by the Conselho Nacional de Procriação Medicamente Assistida and the Entidade Reguladora da Saúde governs clinic licensure, donor registries, and treatment reporting, creating a structured yet evolving competitive environment. Civil society organizations have highlighted public investment concerns and capacity shortfalls, which in turn drive private sector growth and international patient flows to Spain.

Market Structure and Segmentation

The sector is analyzed through a mutually exclusive and collectively exhaustive segmentation framework employing two orthogonal axes: Access/Payer Channel and Clinical Service Complexity. This structure captures the full spectrum of clinic activities and patient origins without overlap, enabling precise mapping of revenue concentration, regulatory exposure, and competitive dynamics.

Access/Payer Channel divides demand into four categories: public system patients (routed via national or regional health services with government funding or subsidies), domestic private patients (self-pay or private insurance), cross-border/international patients (medical tourists seeking ART due to regulation, donor availability, or wait times), and research/clinical trial participants (coordinated by academic or clinical research institutions). Each channel exhibits distinct purchasing behaviors, decision-making hierarchies, and regulatory requirements. Public pathways are subject to waiting lists, age limits, and funding constraints; private channels emphasize speed, service quality, and donor program access; cross-border channels command premium pricing for concierge services and rapid access to advanced modalities; and research channels operate under ethics approvals, grant funding, and strict data governance.

Clinical Service Complexity segments offerings into eight mutually exclusive procedural buckets: diagnostics and low-complexity consults (fertility workups, semen analysis, ovarian reserve testing); first-line interventions (ovulation induction, intrauterine insemination); core ART (IVF, ICSI, frozen embryo replacement, embryo transfer); advanced reproductive technology and genetics (PGT-A/M/SR, endometrial receptivity analysis, AI-assisted embryo selection); third-party reproduction programs (donor egg/sperm/embryo programs, donor matching, and registry management); fertility preservation and cryobanking (elective oocyte cryopreservation, oncology-related preservation, long-term biobanking); surgical and reproductive surgical support (laparoscopy, hysteroscopy, pre-ART surgery); and ancillary non-clinical support services (psychological counseling, legal/administrative support, travel/concierge, language services).

Every clinic activity and patient interaction can be mapped to one payer channel and one service complexity category, generating distinct operational scenarios for revenue modeling, capacity planning, regulatory reporting, and competitive positioning. For example, a cross-border patient receiving a donor egg program represents a high-value, high-complexity scenario with premium pricing, multilingual support, and strict donor registry compliance; a public system patient undergoing core IVF reflects moderate complexity with government funding constraints and waiting list dynamics.

This segmentation directly aligns with regulatory reporting structures (SEF registry in Spain; CNPMA registry in Portugal) and reflects observed market dynamics: public sector waiting lists, private sector pricing differentiation, cross-border patient concentration in Spain, and rising demand for high-complexity services driven by demographic trends (delayed motherhood, higher maternal age, and increased awareness of fertility preservation).

Market Size, Growth, and Revenue Dynamics

The Spain fertility services market was sized at approximately USD 1.66 billion in 2023, anchored by robust private and donor/fertility preservation activity. Using a compound annual growth rate of 6.8 percent for 2024–2030 (as reported by the Horizon Databook), the market is projected to reach approximately USD 1.78 billion in 2024, USD 1.91 billion in 2025, and USD 2.04 billion in 2026. Portugal-specific market sizing is not published in a directly comparable format within the consulted sources; however, regulatory and registry data confirm growing private clinic activity, ongoing public capacity constraints, and expanding donor program oversight.

Revenue concentration is highest in high-complexity services—core ART (IVF/ICSI, frozen embryo cycles), advanced genetics (PGT, endometrial receptivity analysis, AI-assisted embryo selection), third-party reproduction programs, and fertility preservation/cryobanking. These segments require specialized laboratory infrastructure, skilled embryologists, advanced genetic testing capabilities, and robust donor registries, all of which support elevated per-cycle pricing and differentiation. Cross-border patient flows further amplify revenue potential, as international patients typically pay premium pricing for donor access, rapid treatment cycles, and comprehensive concierge services.

Demand drivers include: (1) rising maternal age and delayed parenthood across Europe, which increase the prevalence of age-related infertility and the need for donor eggs and advanced genetic testing; (2) cross-border fertility tourism driven by Spain's permissive donor regulations, donor anonymity, and extensive treatment offerings; (3) growing adoption of preimplantation genetic testing, with PGT usage rising from single digits to approximately 38–49 percent of IVF cycles in Spain over recent registry periods; and (4) rapid expansion of fertility preservation services, including elective oocyte cryopreservation and oncology-related preservation, supported by evolving public and private sector capacity.

Market dynamics reflect a fragmented to moderately consolidated structure. Spain hosts hundreds of fertility clinics, including large multi-clinic networks (IVI-RMA, Instituto Bernabeu, Clinica Tambre, Dexeus Mujer, Ginemed, Vida Fertility, Reproclinic, Institut Marques) and numerous independent providers. This density sustains intense competition while enabling scale advantages for leading networks through standardized protocols, donor bank breadth, and laboratory automation. Portugal's market features fewer centers, with a growing private sector complementing public capacity and a centralized regulatory framework governing donor registries, treatment reporting, and clinic licensure.

Barriers to entry are high, driven by substantial capital requirements for accredited IVF laboratories, cryobank facilities, and donor programs; complex licensing and ongoing registry reporting obligations; and the need for clinical success rates and lab quality to attract domestic and international patients. Regulatory fragmentation between Spain and Portugal increases compliance overhead for entities seeking cross-border activity, while data protection obligations under GDPR add further complexity to patient and donor data handling.

Trends, Innovation, and Technological Transformation

The Iberian fertility clinic sector is undergoing significant transformation across five key dimensions:

1. **Cross-border fertility tourism** remains a central growth vector, with Spain attracting a large share of international patients due to donor policies, anonymity options, and broad ART offerings. Clinics report substantial international patient inflows; Spain is frequently cited as a leading European destination for ART with prominent donor banks and broad treatment menus. This dynamic expands total addressable market and supports higher-value services (donor programs, PGT, cryobanking) beyond resident populations.
2. **Advanced reproductive technology and genetics** are expanding as core differentiators, supported by robust donor banks and registry data in Spain and increasing private uptake in Portugal. PGT adoption has risen substantially, with usage reaching notable shares in Spain and extensive donor banks and registries enabling evidence-based refinement. This trend drives per-cycle value, requires specialized labs and data-management capabilities, and influences competitive positioning.

3. **Fertility preservation and cryobanking** are experiencing rapid growth, supported by public and private sector activity in Spain and growing private uptake in Portugal. SEF registry data show growth in vitrification and cryopreservation cycles; Spanish clinics are expanding egg-freezing services; and private sector activity in Portugal is aligning with preservation and PMA/private pathways. This adds revenue streams, expands service lines, and influences patient acquisition through fertility preservation as a strategic offering.
4. **Regulatory evolution** in Portugal and ongoing public-private mix changes influence payer pathways, access constraints, and clinical trial activity. Portugal's regulatory landscape (INFARMED, ERS, CNPMA) is guiding private growth and donor/registry governance. The ERS study on access constraints and waiting times, CNPMA governance and European atlas policy context, and ongoing updates to PMA, donor registries, and registry reporting shape market dynamics and competition, particularly for private providers.
5. **Digital enablement**, AI, and automation in ART workflows and lab operations are emerging as efficiency and quality drivers. Technology-enabled improvements can raise efficiency, quality, and throughput, with particular relevance for high-volume markets and donor/PGT-heavy services. References to AI/automation support systems within the ART lab value chain, general market commentary on AI adoption in European ART markets, and laboratory automation trends cited in market analyses underscore this nascent but accelerating trend.

Competitive Landscape and Strategic Differentiation

The Iberian fertility clinic sector exhibits a two-tier competitive dynamic: a handful of large, multi-clinic networks competing for international patient flows, and numerous boutique centers differentiating on personalized care, donor options, and advanced technologies. Key players include IVI Fertility (global leader with a large Spanish footprint and multilingual services), Instituto Bernabeu (leading private center with significant international patient focus and broad donor programs), Clinica Tambre (long-established, high-ethics, patient-centric provider with AI/predictive analytics), Dexeus Mujer (premier private sector gynecology and fertility hub with multidisciplinary care and research orientation), Ginemed (high-growth national network with transparent communication and broad service lines), Vida Fertility (boutique, English-friendly option emphasizing complex cases and individualized treatment plans), Reproclinic (boutique, patient-centered clinic network with holistic, compassionate care), and Institut Marques (established Barcelona-based center with integrated services and international patient orientation).

Strategic differentiation occurs along multiple lenses: cost leadership and pricing posture (transparent pricing and predictable cycles, with price competition tempered by donor programs and complex services); proprietary technologies and IP moats (AI-assisted embryo selection, non-invasive PGT using cell-free DNA in culture medium, high-throughput lab automation, and streamlined cryopreservation workflows); distribution networks and channel access (large networks providing broad geographic coverage and international patient coordination; boutique clinics differentiating through multilingual staff and concierge services); and brand ecosystems and patient experience (boutique clinics emphasizing holistic care, emotional support, and English-language accessibility; major groups emphasizing international patient offices, donor banks, and extensive clinical data gathering).

Competitive intensity is rated high, justified by high innovation velocity (AI in embryology, non-invasive genetic testing), substantial price transparency, a large pool of clinics (fragmented landscape with strong networks), meaningful cross-border patient flows, and ongoing regulatory dynamics. Media coverage and public data highlight Europe-leading IVF volumes in Spain and a robust donor ecosystem, all contributing to intense competitive dynamics.

Regulatory, Legal, and Compliance Framework

The regulatory architecture governing the Iberian fertility clinic ecosystem shapes competitive behavior, investment choices, and operational models by defining access pathways (public, private, and international) and aligning them with service complexity. Spain uses a registry-driven reporting ecosystem (SEF) and a broad uptake of private versus public service pathways, alongside cross-border patient inflows that emphasize donor program activity. Portugal features a regulated access regime with public and private components, ongoing regulatory refinements, and a central registry/reporting framework administered by national bodies (CNPMA) and the health regulator (ERS). Cross-border dynamics, patient mobility, and donor/privacy considerations further complicate compliance across both jurisdictions.

Key regulatory bodies include: SEF (Sociedad Española de Fertilidad) in Spain, which operates as a central registry/oversight body linked to ART activity reporting and sectoral data collection; CNPMA (Conselho Nacional de Procriação Medicamente Assistida) in Portugal, serving as the central regulatory authority and registry steward; and ERS (Entidade Reguladora da Saúde) in Portugal, providing health regulatory oversight and monitoring of access, capacity, and related economic/regulatory issues. Cross-border standards and EU data protection are governed at the EU level with GDPR enforcement and interpretations that affect accountable data handling, donor registries, and cross-border care arrangements.

Compliance obligations span five domains: (1) Licensing and registration (obtain and maintain licensure to operate ART clinics and laboratories; ensure physician and embryology staff credentials meet regulatory expectations; participate in mandatory registries and comply with donor program reporting and patient consent standards); (2) Data protection and privacy (compliance with GDPR for patient data handling, donor anonymity and consent processes, and cross-border data transfers; data governance for fertility registries and clinical information systems; safeguarding sensitive health information within and across clinics); (3) Environmental regulation (compliance with medical waste management, infection control, chemical and sterilization practices, and general laboratory environmental standards applicable to ART labs and support facilities); (4) Financial disclosure and reporting (public sector reporting requirements for patients under public or subsidized pathways; private clinic financial compliance with billing, pricing transparency where applicable, and regulatory reporting tied to registries and payer interactions); and (5) Health and safety (patient safety protocols, infection prevention, occupational safety for clinic staff, and risk management within ART labs and clinical settings).

Enforcement trends include regular registry reporting audits and licensing inspections; penalties for non-compliance with reporting or licensing requirements; heightened scrutiny of cross-border patient activities and donor programs within EU privacy and healthcare frameworks; and ongoing harmonization of clinical safety standards across public/private sector interfaces

Customer Segmentation, Go-To-Market Insights, and Retention Mechanics

Customer segmentation deconstructs demand by payer/access channel and clinical service complexity, revealing distinct buying behaviors, decision-making units, and procurement dynamics. Public system patients are routed through public health authorities with government funding or subsidized access, with treatment consideration aligning with public wait times, clinical eligibility rules, and regional capacity. Decision-making units involve hospital physicians, departmental heads, regional health authorities, and procurement/budget committees governing public funding for ART services. Procurement complexity is high, governed by public budget cycles, regional or national procurement rules, and compliance reporting to registries. Patient choice is constrained by eligibility criteria, waiting lists, and funding rules.

Domestic private patients opt for private clinics or private hospital units due to shorter wait times, perceived convenience, or access to certain modalities. Decisions are patient-driven with influence from private insurers' pre-authorization processes. Decision-making units include the patient and, when applicable, a private insurer or employer-provided benefit manager. Procurement complexity is lower, with predominantly private billing and potential insurer pre-authorization, and more direct consumer-level engagement.

Cross-border/international patients travel to Iberia primarily to access ART, frequently motivated by donor availability, regulatory conditions, wait times, and cost considerations. Decision cycles are influenced by clinic reputation, success rates, reimbursement mechanisms, or concierge services. Decision-making units include the patient, travel coordinators or agents, donor matching teams, and, in some cases, local insurance arrangements or reimbursement discussions arranged through clinics. Procurement complexity is high, involving regulatory compliance, visa/work-up logistics, cross-border privacy and data handling, and coordination with international registries. Revenue capture often involves multi-party coordination and service bundles (treatment, accommodation, concierge).

Research/clinical trial participants are enrolled in protocols coordinated by clinics, hospitals, or academic centers, with enrollment driven by protocol availability, inclusion criteria, and study site capacity. Decision-making units include research coordinators, principal investigators, ethics committees, institutional review boards, and regulatory bodies. Procurement complexity is high, including ethical approvals, grant or trial funding terms, and detailed regulatory reporting; patient consent processes and trial governance add layers of complexity.

Sales and distribution modalities encompass direct channels (in-clinic patient pathways and physician referrals within hospital and private practice networks; patient outreach through clinic websites, telemedicine triage, and centralized call centers; field engagement with fertility specialists and obstetric/gynecology networks to drive early diagnostics and treatment plans); indirect channels (insurers, employer wellness programs, and private health plans that cover ART where applicable; medical tourism facilitators and partner clinics, especially for cross-border patients seeking donor options or specific regulatory environments; academic and hospital collaborations that feed referrals for advanced genetic testing or donor programs); platform-based channels (marketplaces or platform ecosystems that help patients discover clinics, compare success metrics, and access donor registries; donor banks and registry platforms that enable matchmaking for third-party reproduction; API integrations with laboratory information systems and electronic health

records to streamline data portability and interoperability); hybrid GTM patterns (a combination of private care quality signals, public system segmentation disclosures, and international patient concierge services to optimize overall volume across payer types; co-located clinics with integrated cross-border service capabilities and streamlined patient journeys for both domestic and international patients); and emerging distribution vectors (AI-assisted donor matching, predictive analytics for cycle planning, and enhanced data sharing with registries to improve transparency and confidence; partnerships that bundle fertility preservation with oncology care pathways, expanding value propositions for patients).

Retention mechanics center on friction points (integration effort with different electronic health record systems, data portability across clinics, and inter-clinic transfer of medical records; onboarding friction for new patients, including consent processes, donor program requirements, and genetic testing authorizations; data portability for patient ability to transfer treatment records and cryobank assets between providers); lock-in levers (long-term contracts and ongoing cryopreservation arrangements that bind patients to a clinic's biobank infrastructure; workflow dependencies in embryology and donor program workflows that create continuity requirements for successive cycles; proprietary integrations through clinic-specific lab protocols and IT ecosystems that raise switching costs for future cycles); loyalty assets (brand affinity built on demonstrated success rates, high-quality patient support, strong clinician reputations, and supportive patient communities; support quality and patient services including multilingual care, concierge travel assistance for international patients, and comprehensive psychosocial resources; community and registry engagement through active involvement with patient advocacy groups and transparent reporting to registries that reinforce trust); and high-churn risk zones versus high-retention segments (higher churn risk is associated with cross-border patients who may test multiple providers or seek alternate donor options; lower churn risk tends to be in sustained donor program participation and long-term cryopreservation arrangements, where asset-intensive commitments incentivize ongoing engagement).

Industry Attractiveness, Risk Profile, and Strategic Outlook

Industry attractiveness is assessed through Porter's Five Forces and structural return on invested capital potential. Buyer power is moderate, with strongest leverage in price for standard diagnostics and low-complexity services and strengthened vendor power in donor/PGT ecosystems for high-value cycles. Public sector patients are subject to waited access, eligibility criteria, and pricing/government funding constraints, which dampen direct price leverage on clinics. Domestic private patients exercise greater price sensitivity and value emphasis on cycle efficiency, donor options, and testing capabilities. Cross-border patients typically pay premium for speed, donor breadth, and regulatory convenience, improving clinics' pricing power in international channels.

Supplier power is moderate, as suppliers include lab equipment providers, IVF media, medications (gonadotropins), cryobank solutions, and IT/data systems for registries. The market features multiple suppliers and relatively standardized inputs, limiting any single supplier's bargaining leverage. Criticality is higher for high-spec lab equipment, automation software, and donor registries, but competition among suppliers mitigates pricing risk.

Barriers to entry are high, driven by high capital requirements for accredited IVF labs, cryobank facilities, donor programs, and regulatory compliance; complex licensing, ongoing registry reporting (SEF in Spain; CNPMA/ERS in Portugal), and donor governance obligations; and regulatory fragmentation between Spain and Portugal, which increases compliance overhead for new entrants seeking cross-border activity.

Rivalry intensity is high, reflecting a fragmented to moderately consolidated market structure in Spain, with large networks (IVI-RMA, Bernabeu, Tambre, Dexeus, Ginemed) and numerous independents creating vigorous competition for price, outcomes, and international patient flows. Portugal presents a smaller but growing private sector within a regulated public framework, contributing to competitive pressure in a different regulatory environment.

Threat of substitution is low to moderate. Substitutes to ART are limited in the near term for most infertility cases; however, patients may consider alternative destinations (medical tourism networks) or non-ART fertility preservation strategies in some contexts. Advances in non-invasive genetics and AI in embryo assessment could reframe service mix, though they complement rather than replace ART in practice.

Structural ROIC potential is rated moderate. Core ART (IVF/ICSI) and adjacent high-value services (PGT, donor programs, cryobanking) yield elevated per-cycle margins relative to diagnostics; however, margins vary by payer mix (public vs private vs international) and regulatory overhead. Capital intensity is substantial, with lab infrastructure, cryobiology facilities, and skilled embryology staff implying upfront and ongoing capital expenditure; automation and AI enable efficiency gains but require continued investment. Pricing power is stronger in private and cross-border segments, particularly for donor programs, PGT, and preservation services; public pathways limit pricing flexibility. Scalability is high in Spain due to dense clinic networks, donor capacity, and cross-border demand; more constrained in Portugal where public framework and regulatory evolution shape capacity expansion.

Risk landscape mapping identifies four primary risk categories: (1) Regulatory risk (Spain: SEF registry reporting, donor governance, and compliance with public/private funding rules; Portugal: INFARMED/ERS/CNPMA governance, PMA framework evolution, donor registry oversight, and cross-border considerations; cross-border data sharing and GDPR compliance add complexity for patient and donor data handling); (2) Technological risk (adoption of AI in embryo selection, non-invasive genetics testing, and lab automation introduces both productivity gains and dependency on proprietary tech and data standards; IP considerations and the need for continual validation of novel genetic tests and analytics); (3) Operational risk (talent acquisition and retention in embryology and genetics; regional capacity constraints; coordination for cross-border patient journeys; cryobank management and long-term asset care; dependence on consistent supply of lab consumables and medications; potential disruptions in supply chains or price volatility); and (4) Supply chain risk (reliance on global suppliers for IVF media, lab equipment, cryo-storage infrastructure, and genetic testing reagents; exposure to price fluctuations and regulatory export controls; donor program governance and registry integrity introduce additional operational dependencies).

Early red flags and strategic unknowns include: geopolitical fragility and regulatory shifts that could reconfigure cross-border access, donor anonymity, and patient eligibility criteria; input scarcity and material price volatility for gonadotropins, culture media, and lab automation components; potential overreliance on cross-border demand in Spain, creating sensitivity to macro shifts in travel restrictions, currency fluctuations, or EU policy changes; growth in private capacity in Portugal that could attract investment but is contingent on continued regulatory clarity and registry governance; and concentration risk around high-value segments (PGT, donor programs, cryobanking) if donor pools tighten or regulatory limits constrain access.

Strategic Recommendations:

The Iberian Fertility Clinics Sector presents a high-to-moderate investment opportunity, with Spain offering a high-opportunity profile given its size, cross-border demand, donor/PGT capability, and private sector breadth, and Portugal presenting a moderate-opportunity profile due to regulatory constraints and evolving private capacity. Profitability outlook is moderate, reflecting high-value service friction (donor, PGT, cryopreservation) combined with regulatory reporting costs and capital intensity. Profitability is disproportionately driven by complex, high-margin cycles and international patients, with sensitivity to payer mix and regulatory changes.

Strategic guidance centers on incumbents with strong donor networks, PGT capability, and cryobank assets, as well as those leveraging cross-border capabilities and lab automation. Entities with robust data governance, registry reporting efficiency, and international patient concierge capabilities are positioned to capitalize on high-value segments. Those facing regulatory fragmentation or supply-chain vulnerabilities should monitor risk exposure and capital-allocation discipline. The MECE segmentation framework (Access/Payer × Clinical Service Complexity) remains a robust tool for ongoing monitoring of capacity, pricing, regulation, and competitive dynamics within Spain and Portugal.

Revenue concentration is expected to remain highest in high-complexity services (core ART, advanced genetics, third-party reproduction programs, fertility preservation/cryobanking) that require specialized laboratory infrastructure, skilled embryologists, advanced genetic testing capabilities, and robust donor registries. Cross-border patient flows will continue to amplify revenue potential, as international patients typically pay premium pricing for donor access, rapid treatment cycles, and comprehensive concierge services. Demographic trends (delayed motherhood, higher maternal age, and increased awareness of fertility preservation) will sustain demand growth, particularly for donor eggs, PGT, and fertility preservation services.

Competitive positioning will be driven by: (1) scale advantages through standardized protocols, donor bank breadth, and laboratory automation; (2) differentiation via AI-assisted embryo selection, non-invasive PGT, high-throughput lab automation, and streamlined cryopreservation workflows; (3) brand ecosystems built on demonstrated success rates, high-quality patient support, strong clinician reputations, and supportive patient communities; and (4) cross-border capabilities including multilingual staff, concierge services, international patient offices, donor banks, and extensive clinical data gathering.

Regulatory alignment and compliance excellence will be critical, as ongoing registry reporting obligations, donor governance, data protection (GDPR), and cross-border data sharing requirements shape clinic strategy, capacity allocation, pricing dynamics, and data management practices. Clinics with robust data governance, registry reporting efficiency, and international patient concierge capabilities will be best positioned to capture high-value segments and navigate regulatory fragmentation across Spain and Portugal.

In conclusion, the Iberian Fertility Clinics Sector is characterized by a dominant Spanish market with substantial cross-border demand, a robust private provider base, and a growing fertility preservation and genetic testing segment. Portugal contributes through a regulated public framework with expanding private activity and ongoing regulatory refinements. Market strategy should account for high-value services (PGT, donor programs, cryobanking) and the importance of cross-border patient services in Spain. Data availability is strongest for Core ART and Advanced ART/PGT in Spain, with regulatory clarity in both countries guiding reporting and compliance. The MECE segmentation framework provides a rigorous, non-overlapping structure to characterize the sector, map critical commercial and operational distinctions, and support targeted strategic analyses of capacity, regulation, pricing, and competitive positioning while reflecting observed market dynamics in Spain and Portugal.

Appendix | List of Sources

Customer & Go-To-Market Insights:

Title: Spain Fertility Services Market Research Report, 2030
Author/Publisher: Actual Market Research
Date: (accessed 2025)
URL: https://www.actualmarketresearch.com/product/spain-fertility-services-market
Used for: Segmentation categories and market trend synthesis (procedures, donor programs, private clinic chains).

Title: APF_press-kit_250520.pdf
Author/Publisher: APFertilidade
Date: (2025)
URL: https://apfertilidade.org/wp-content/uploads/2025/05/APF_press-kit_250520.pdf
Used for: Civil society perspectives in Portugal, public investment and capacity concerns.

Title: Conselho Nacional de Procriação Medicamente Assistida (CNPMA) — official portal pages (PMA in Portugal, Atlas and legal/regulatory content)
Author/Publisher: Conselho Nacional de Procriação Medicamente Assistida (CNPMA)
Date: (accessed 2024–2025)
URL: https://www.cnpma.org.pt/cidadaos; https://www.cnpma.org.pt/destaques/Paginas/European-Atlas-of-Fertility-Treatmen-Policies-2024.aspx
Used for: Portuguese regulatory framework, registry role and legal context.

Title: Estudo | Acesso a Procriação Medicamente Assistida
Author/Publisher: Entidade Reguladora da Saúde (ERS)
Date: (2025-12-23) (executive summary posted)
URL: https://www.ers.pt/pt/atividade/regulacao-economica/selecionar/estudos/lista-de-estudos/estudo-acesso-a-procriacao-medicamente-assistida/
Used for: Portugal public access constraints, waiting times, public/private center counts and regional availability.

Title: Assisted reproduction in Spain, outcome and socio-economic determinants
Author/Publisher: Figueira, R., et al. (BMC/PMC)
Date: (2021)
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8259134/
Used for: Comparative outcomes, socio-economic determinants and public/private differences in Spain.

Title: Spain leads in vitro fertilization treatments performed in Europe
Author/Publisher: Instituto Bernabeu (news)
Date: (2024-08-02)
URL: https://www.institutobernabeu.com/en/news/spain-leads-in-vitro-fertilization-treatments-performed-in-europe/
Used for: Spain market positioning, cross-border patient commentary and donor program prevalence.

Title: According to the SEF Registry, reproductive treatments increased by 29% in Spain during the year 2021
Author/Publisher: IVI Global Education
Date: (2023)
URL: https://iviglobaleducation.com/en/according-to-the-sef-registry-reproductive-treatments-increased-by-29-in-spain-during-the-year-2021/
Used for: Spain production volumes, SEF registry reference and role of ART volumes.

Title: Spain Assisted Reproductive Technology Market Overview and Executive Summary
Author/Publisher: MarketsandMarkets / MNM
Date: (2024–2025)
URL: https://mnm.digitalpress.blog/spain-assisted-reproductive-technology-market-benchmarking-with-global-trends/
Used for: Market drivers (delayed motherhood), AI/technology trends and role of medical tourism.

Title: A long-term analysis of the Portuguese assisted reproductive technologies data registry 1997–2005
Author/Publisher: Silva, V.; Calhaz-Jorge, C. (Acta Obstet Ginecol Port)
Date: (2010)
URL: https://www.fspog.org/images/editor2/2010-1_artigo_original_5.pdf
Used for: Historical registry methodology and Portuguese ART indicators and reporting

Competitive Landscape:

Title: IVF in Spain – Reviews, Best Clinics and Law - Fertility Clinics Abroad
Author/Publisher: Fertility Clinics Abroad
Date: 2022-01-01
URL: https://www.fertilityclinicsabroad.com/ivf-clinics-abroad/ivf-in-spain-reviewed-by-experts/
Used for: Regulatory context and price/regulatory considerations

Title: Best IVF Clinics in Spain 2025 – Top Fertility Options
Author/Publisher: Fertility Clinics Abroad
Date: 2025-12-11
URL: https://www.fertilityclinicsabroad.com/clinics/spain/
Used for: Identification of top Spanish clinics and service breadth

Title: Spain leads in vitro fertilization treatments performed in Europe
Author/Publisher: Instituto Bernabeu (Institute Bernabeu)
Date: 2024-08-02
URL: https://www.institutobernabeu.com/en/news/spain-leads-in-vitro-fertilization-treatments-performed-in-europe/
Used for: Market leadership claim of Spain in IVF volume and regulatory environment supporting international patients

Title: IVI-RMA is the largest Assisted Reproduction group in the world
Author/Publisher: IVI Fertility
Date: 2024-01-01
URL: https://ivi-fertility.com
Used for: Competitive positioning of IVI as a global scale player and its Spanish footprint

Title: Spain In Vitro Fertilization Market Overview and Executive Summary
Author/Publisher: MarketsandMarkets
Date: 2024-12-01
URL: https://mnm.digitalpress.blog/spain-in-vitro-fertilization-market-overview-and-executive-summary/
Used for: Market size, growth drivers, and technology trends in Spain's IVF market

Title: Top 5 IVF Fertility Centers in Spain Crafting Love Stories
Author/Publisher: Medical Tourism Magazine
Date: 2022-01-01
URL: https://www.magazine.medicaltourism.com/article/top-5-ivf-fertility-centers-in-spain-crafting-love-stories
Used for: Positioning of Spain as a leading destination and clinic ecosystem

Legal, Regulatory and Compliance:

Title: APFertilidade, APF_press-kit_250520.pdf
Author/Publisher: APFertilidade
Date: 2025
URL: https://apfertilidade.org/wp-content/uploads/2025/05/APF_press-kit_250520.pdf
Used for: Civil society perspectives in Portugal, public investment and capacity concerns

Title: Spain Fertility Services Market Research Report, 2030
Author/Publisher: Actual Market Research
Date: 2025
URL: https://www.actualmarketresearch.com/product/spain-fertility-services-market
Used for: Segmentation categories and market trend synthesis (procedures, donor programs, private clinic chains)

Title: Conselho Nacional de Procriação Medicamente Assistida (CNPMA) — official portal pages
Author/Publisher: CNPMA
Date: 2024–2025
URL: https://www.cnpma.org.pt/cidadaos
Used for: Portuguese regulatory framework, registry role and legal context

Title: Estudo | Acesso a Procriação Medicamente Assistida
Author/Publisher: Entidade Reguladora da Saúde (ERS)
Date: 2025-12-23
URL: https://www.ers.pt/pt/atividade/regulacao-economica/selecionar/estudos/lista-de-estudos/estudo-acesso-a-procriacao-**medicamente**-assistida/
Used for: Portugal public access constraints, waiting times, public/private center counts and regional availability

Title: Assisted reproduction in Spain, outcome and socio-economic determinants
Author/Publisher: Figueira, R., et al. (BMC/PMC)
Date: 2021
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8259134/
Used for: Comparative outcomes, socioeconomic determinants and public/private differences in Spain

Title: Spain leads in vitro fertilization treatments performed in Europe
Author/Publisher: Instituto Bernabeu (news)
Date: 2024-08-02
URL: https://www.institutobernabeu.com/en/news/spain-leads-in-vitro-fertilization-treatments-performed-in-europe/
Used for: Spain market positioning, cross-border patient commentary and donor program prevalence

Title: According to the SEF Registry, reproductive treatments increased by 29% in Spain during the year 2021
Author/Publisher: IVI Global Education
Date: 2023
URL: https://iviglobaleducation.com/en/according-to-the-sef-registry-reproductive-treatments-increased-by-29-in-spain-during-the-year-2021/
Used for: Spain production volumes, SEF registry reference and role of ART volumes

Title: Spain Assisted Reproductive Technology Market Overview and Executive Summary
Author/Publisher: MarketsandMarkets (MNM)
Date: 2024–2025
URL: https://mnm.digitalpress.blog/spain-assisted-reproductive-technology-market-benchmarking-with-global-trends/
Used for: Market drivers (delayed motherhood), AI/technology trends and role of medical tourism

Title: A long-term analysis of the Portuguese assisted reproductive technologies data registry 1997–2005
Author/Publisher: Silva, V., & Calhaz-Jorge, C.
Date: 2010
URL: https://www.fspog.org/images/editor2/2010-1_artigo_original_5.pdf
Used for: Historical registry methodology and Portuguese ART indicators and reporting

PEST Analysis:

Title: Spain Fertility Services Market Research Report, 2030
Author/Publisher: Actual Market Research
Date: 2025
URL: https://www.actualmarketresearch.com/product/spain-fertility-services-market
Used for: Segmentation categories and market trend synthesis (procedures, donor programs, private clinic chains)

Title: APFertilidade press-kit_250520.pdf
Author/Publisher: APFertilidade
Date: 2025
URL: https://apfertilidade.org/wp-content/uploads/2025/05/APF_press-kit_250520.pdf
Used for: Civil society perspectives in Portugal, public investment and capacity concerns

Title: Conselho Nacional de Procriação Medicamente Assistida (CNPMA) — official portal pages
Author/Publisher: CNPMA
Date: 2024–2025
URL: https://www.cnpma.org.pt/cidadaos
Used for: Portuguese regulatory framework, registry role and legal context

Title: Estudo | Acesso a Procriação Medicamente Assistida
Author/Publisher: Entidade Reguladora da Saúde (ERS)
Date: 2025-12-23
URL: https://www.ers.pt/pt/atividade/regulacao-economica/selecionar/estudos/lista-de-estudos/estudo-acesso-a-procriacao-medicamente-assistida/
Used for: Portugal public access constraints, waiting times, public center counts and regional availability

Title: Assisted reproduction in Spain, outcome and socio-economic determinants
Author/Publisher: Figueira, R. et al.
Date: 2021
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8259134/
Used for: Comparative outcomes, socioeconomic determinants and public/private differences in Spain

Title: Spain leads in vitro fertilization treatments performed in Europe
Author/Publisher: Instituto Bernabeu (news)
Date: 2024-08-02
URL: https://www.institutobernabeu.com/en/news/spain-leads-in-vitro-fertilization-treatments-performed-in-europe/
Used for: Spain market positioning, cross-border patient commentary and donor program prevalence

Title: According to the SEF Registry, reproductive treatments increased by 29% in Spain during the year 2021
Author/Publisher: IVI Global Education
Date: 2023
URL: https://iviglobaleducation.com/en/according-to-the-sef-registry-reproductive-treatments-increased-by-29-in-spain-during-the-year-2021/
Used for: Spain production volumes, SEF registry reference and role of ART volumes

Title: Spain Assisted Reproductive Technology Market Overview and Executive Summary
Author/Publisher: MarketsandMarkets
Date: 2024–2025
URL: https://mnm.digitalpress.blog/spain-assisted-reproductive-technology-market-benchmarking-with-global-trends/
Used for: Market drivers (delayed motherhood), AI/technology trends and role of medical tourism

Title: A long-term analysis of the Portuguese assisted reproductive technologies data registry 1997–2005
Author/Publisher: Silva V., Calhaz-Jorge C.
Date: 2010
URL: https://www.fspog.org/images/editor2/2010-1_artigo_original_5.pdf
Used for: Portuguese registry indicators and historical context

Sector Trends & Innovation:

Title: Spain Fertility Services Market Analysis
Author/Publisher: Acuitas Health Analytics
Date: 2023–2033
URL: https://acuitashealthanalytics.com/report/healthcare-services/spain-fertility-service-market-analysis/
Used for: Spain TAM projections and market dynamics.

Title: Spain Fertility Services Market Research Report, 2030
Author/Publisher: Actual Market Research
Date: 2025
URL: https://www.actualmarketresearch.com/product/spain-fertility-services-market
Used for: Segmentation categories and market trend synthesis (procedures, donor programs, private clinic chains).

Title: APF_press-kit_250520.pdf
Author/Publisher: APFertilidade
Date: 2025
URL: https://apfertilidade.org/wp-content/uploads/2025/05/APF_press-kit_250520.pdf
Used for: Civil society perspectives in Portugal, public investment and capacity concerns.

Title: Conselho Nacional de Procriação Medicamente Assistida (CNPMA) — official portal pages
Author/Publisher: CNPMA
Date: 2024
URL: https://www.cnpma.org.pt/cidadaos
Used for: Portuguese regulatory framework, registry role, and legal context.

Title: RELATÓRIO DE ATIVIDADES CNPMA 2022
Author/Publisher: CNPMA
Date: 2022
URL:https://www.cnpma.org.pt/cnpma/Documents/PlanosERelatoriosAnuaisDeAtividade/RELAT%C3%93RIO%20DE%20ATIVIDADES%20CNPMA%202022.pdf
Used for: Portugal activity and regulatory oversight.

Title: RELATÓRIO DE ATIVIDADES CNPMA 2023
Author/Publisher: CNPMA
Date: 2023
URL:https://www.cnpma.org.pt/cnpma/Documents/PlanosERelatoriosAnuaisDeAtividade/RELAT%C3%93RIO%20DE%20ATIVIDADES%20CNPMA%202023.pdf
Used for: Portugal activity and regulatory oversight.

Title: RELATÓRIO DE ATIVIDADES CNPMA 2024
Author/Publisher: CNPMA
Date: 2024
URL:https://www.cnpma.org.pt/cnpma/Documents/PlanosERelatoriosAnuaisDeAtividade/RELATÓRIO%20DE%20ATIVIDADES%20CNPMA%202024.pdf
Used for: Portugal activity and regulatory oversight.

Title: European Atlas of Fertility Treatment Policies 2024
Author/Publisher: CNPM and European Atlas team
Date: 2024
URL: https://www.cnpma.org.pt/destaques/Documents/FERTIL-Atlas_EN-2024.pdf
Used for: Portugal/EU policy context and donor frameworks.

Title: Is the use of PGT-A effective in patients over 40 years of age? (COGI 2024)
Author/Publisher: COGI
Date: 2024/2025
URL: https://grupointernacionalur.com/wp-content/uploads/2025/03/COGI-2024.pdf
Used for: PGT adoption and outcomes data.

Title: Regulatory, Pricing and Reimbursement Overview – Cuatrecasas
Author/Publisher: Cuatrecasas
Date: 2021
URL: https://www.cuatrecasas.com/resources/the-pharma-legal-handbook-portugal-2021-pharmaboardroom-preview-62bf152edd5bf198605525.pdf
Used for: Portugal regulatory framework and reimbursement structure.

Title: Estudo | Acesso a Procriação Medicamente Assistida
Author/Publisher: Entidade Reguladora da Saúde (ERS)
Date: 2025-12-23
URL: https://www.ers.pt/pt/atividade/regulacao-economica/selecionar/estudos/lista-de-estudos/estudo-acesso-a-procriacao-medicamente-assistida/
Used for: Portugal public access constraints, waiting times, public/private center counts and regional availability.

Title: Assisted reproduction in Spain, outcome and socio-economic determinants
Author/Publisher: Figueira, R., et al.
Date: 2021
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8259134/
Used for: Comparative outcomes, socioeconomic determinants, and public/private differences in Spain.

Title: Spain leads in vitro fertilization treatments performed in Europe
Author/Publisher: Instituto Bernabeu
Date: 2024-08-02
URL: https://www.institutobernabeu.com/en/news/spain-leads-in-vitro-fertilization-treatments-performed-in-europe/
Used for: Spain market positioning, cross-border patient commentary, and donor program prevalence.

Title: According to the SEF Registry, reproductive treatments increased by 29% in Spain during the year 2021
Author/Publisher: IVI Global Education
Date: 2023
URL: https://iviglobaleducation.com/en/according-to-the-sef-registry-reproductive-treatments-increased-by-29-in-spain-during-the-year-2021/
Used for: Spain production volumes, SEF registry reference, and role of ART volumes.

Title: Spain Assisted Reproductive Technology Market Overview and Executive Summary
Author/Publisher: MarketsandMarkets
Date: 2024–2025
URL: https://mnm.digitalpress.blog/spain-assisted-reproductive-technology-market-benchmarking-with-global-trends/
Used for: Market drivers (delayed motherhood), AI/technology trends, and role of medical tourism.

Title: Other cited market perspectives (MarketsandMarkets and Nova One Advisor) for European market growth and technology trends
Author/Publisher: MarketsandMarkets / Nova One Advisor
Date: Various
URL: Various
Used for: Context on European market growth and technology trends in ART.

Title: Portugal – Medicinal Regulation and Infarmed
Author/Publisher: PLMJ Life Sciences
Date: 2023
URL: https://www.plmj.com/xms/files/07_Guias_e_Manuais/2023/015_PORTUGAL_LP.pdf
Used for: Portugal regulatory landscape and clinical trials environment.

Title: Registro SEF 2021, SEF Registry Report
Author/Publisher: SEF (Spanish Fertility Society)
Date: 2021
URL: https://www.registrosef.com/public/docs/sef2021_IAFIV.pdf
Used for: Spain IVF cycles, IUI volumes, embryo transfer, distributions by age, and public/private trends.

Title: A long-term analysis of the Portuguese assisted reproductive technologies data registry 1997–2005
Author/Publisher: Silva, V., & Calhaz-Jorge, C.
Date: 2010
URL: https://www.fspog.org/images/editor2/2010-1_artigo_original_5.pdf
Used for: Historical registry methodology and Portuguese ART indicators and reporting.

Title: The register of oocytes and sperm donors in Spain has started
Author/Publisher: URH
Date: 2022
URL: https://www.urh.es/en/registrer-oocytes-sperm-donors/
Used for: Donor registry development in Spain

Sector Attractiveness & Risks:

Title: Spain Fertility Services Market Analysis
Author/Publisher: Acuitas Health Analytics
Date: 2023
URL: https://acuitashealthanalytics.com/report/healthcare-services/spain-fertility-service-market-analysis/
Used for: Spain TAM projections and market dynamics

Title: Spain Fertility Services Market Research Report, 2030
Author/Publisher: Actual Market Research
Date: 2025
URL: https://www.actualmarketresearch.com/product/spain-fertility-services-market
Used for: Segmentation categories and market trend synthesis (procedures, donor programs, private clinic chains)

Title: APFertilidade, APF_press-kit_250520.pdf
Author/Publisher: APFertilidade
Date: 2025
URL: https://apfertilidade.org/wp-content/uploads/2025/05/APF_press-kit_250520.pdf
Used for: Civil society perspectives in Portugal, public investment and capacity concerns

Title: RELATÓRIO DE ATIVIDADES CNPMA 2022
Author/Publisher: CNPMA
Date: 2022
URL:https://www.cnpma.org.pt/cnpma/Documents/PlanosERelatoriosAnuaisDeAtividade/RELAT%C3%93RIO%20DE%20ATIVIDADES%20CNPMA%202022.pdf
Used for: Portugal activity and regulatory oversight

Title: RELATÓRIO DE ATIVIDADES CNPMA 2023
Author/Publisher: CNPMA
Date: 2023
URL:
https://www.cnpma.org.pt/cnpma/Documents/PlanosERelatoriosAnuaisDeAtividade/RELAT%C3%93RIO%20DE%20ATIVIDADES%20CNPMA%202023.pdf
Used for: Portugal activity and regulatory oversight

Title: RELATÓRIO DE ATIVIDADES CNPMA 2024
Author/Publisher: CNPMA
Date: 2024
URL:
https://www.cnpma.org.pt/cnpma/Documents/PlanosERelatoriosAnuaisDeAtividade/RELAT%C3%93RIO%20DE%20ATIVIDADES%20CNPMA%202024.pdf
Used for: Portugal activity and regulatory oversight

Title: Conselho Nacional de Procriação Medicamente Assistida (CNPMA) — official portal pages
Author/Publisher: CNPMA
Date: 2024–2025
URL: https://www.cnpma.org.pt/cidadaos
Used for: Portuguese regulatory framework, registry role and legal context

Title: European Atlas of Fertility Treatment Policies 2024
Author/Publisher: CNPM and European Atlas team
Date: 2024
URL: https://www.cnpma.org.pt/destaques/Documents/FERTIL-Atlas_EN-2024.pdf
Used for: Portugal/EU policy context and donor frameworks

Title: Is the use of PGT-A effective in patients over 40 years of age?
Author/Publisher: COGI
Date: 2024
URL: https://grupointernacionalur.com/wp-content/uploads/2025/03/COGI-2024.pdf
Used for: PGT adoption and outcomes data

Title: Regulatory, Pricing and Reimbursement Overview – Cuatrecasas
Author/Publisher: Cuatrecasas
Date: 2021
URL: https://www.cuatrecasas.com/resources/the-pharma-legal-handbook-portugal-2021-pharmaboardroom-preview-62bf152edd5bf198605525.pdf
Used for: Portugal regulatory framework and reimbursement structure

Title: Estudo | Acesso a Procriação Medicamente Assistida
Author/Publisher: Entidade Reguladora da Saúde (ERS)
Date: 2025-12-23
URL: https://www.ers.pt/pt/atividade/regulacao-economica/selecionar/estudos/lista-de-estudos/estudo-acesso-a-procriacao-medicamente-assistida/
Used for: Portugal public access constraints, waiting times, public/private center counts and regional availability

Title: Assisted reproduction in Spain, outcome and socio-economic determinants
Author/Publisher: Figueira, R. et al.
Date: 2021
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8259134/
Used for: Comparative outcomes, socio-economic determinants and public/private differences in Spain

Title: Spain leads in vitro fertilization treatments performed in Europe
Author/Publisher: Instituto Bernabeu
Date: 2024-08-02
URL: https://www.institutobernabeu.com/en/news/spain-leads-in-vitro-fertilization-treatments-performed-in-europe/
Used for: Spain market positioning, cross-border patient commentary and donor program prevalence

Title: According to the SEF Registry, reproductive treatments increased by 29% in Spain during the year 2021
Author/Publisher: IVI Global Education
Date: 2023
URL: https://iviglobaleducation.com/en/according-to-the-sef-registry-reproductive-treatments-increased-by-29-in-spain-during-the-year-2021/
Used for: Spain production volumes, SEF registry reference and role of ART volumes

Title: Spain Assisted Reproductive Technology Market Overview and Executive Summary
Author/Publisher: MarketsandMarkets
Date: 2024–2025
URL: https://mnm.digitalpress.blog/spain-assisted-reproductive-technology-market-benchmarking-with-global-trends/
Used for: Market drivers (delayed motherhood), AI/technology trends and role of medical tourism

Title: MarketsandMarkets – Spain IVF Market Overview
Author/Publisher: MarketsandMarkets
Date: 2024
URL: https://mnm.digitalpress.blog/spain-in-vitro-fertilization-market-overview-and-executive-summary/
Used for: Market size, growth drivers and technology trends in Spain's IVF market

Title: Portugal – Medicinal Regulation and Infarmed
Author/Publisher: PLMJ Life Sciences
Date: 2023
URL: https://www.plmj.com/xms/files/07_Guias_e_Manuais/2023/015_PORTUGAL_LP.pdf
Used for: Portugal regulatory landscape and clinical trials environment

Title: Registro SEF 2021, SEF Registry Report
Author/Publisher: SEF (Spanish Fertility Society)
Date: 2021
URL: https://www.registrosef.com/public/docs/sef2021_IAFIV.pdf
Used for: Spain IVF cycles, IUI volumes, embryo transfer, distributions by age, and public/private trends

Title: A long-term analysis of the Portuguese assisted reproductive technologies data registry 1997–2005
Author/Publisher: Silva V., Calhaz-Jorge C.
Date: 2010
URL: https://www.fspog.org/images/editor2/2010-1_artigo_original_5.pdf
Used for: Historical registry methodology and Portuguese ART indicators and reporting

Title: The register of oocytes and sperm donors in Spain has started
Author/Publisher: URH
Date: 2022
URL: https://www.urh.es/en/registrer-oocytes-sperm-donors/
Used for: Donor registry development in Spain

Want to Talk?

Luís Bessa Mendes

luis.bm@seestem.eu

M.ES:+34 657 457 033

M.PT: +351 91 605 3202